Meeting
2012 Genitourinary Cancers Symposium
Testosterone suppression: Impact of testosterone level on disease progression in advanced prostate cancer.
Authors
Shawn Dason
Division of Urology, McMaster University, Hamilton, ON, Canada
Shawn Dason , Justin Tong , Christopher Brian Allard , Bobby Shayegan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 30, 2012 (suppl 5; abstr 46)
DOI
10.1200/jco.2012.30.5_suppl.46
Abstract #
46
Poster Bd #
C12
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
Effect of Gtx-758, an ERα agonist, on serum-free testosterone and serum PSA in men with advanced prostate cancer.
First Author: Evan Y. Yu
Poster
2024 ASCO Genitourinary Cancers Symposium
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy (iADT) with relugolix.
First Author: Patrick Campbell
Poster
2020 Genitourinary Cancers Symposium
Determination of the ability of a novel, long-acting subcutaneous GnRH antagonist, VERU-100, to castrate without a testosterone surge in a rat model.
First Author: Robert H. Getzenberg
Poster
2014 Genitourinary Cancers Symposium
Optimal testosterone suppression on medical ADT should strive to suppress free testosterone levels to levels similar to orchiectomy: What is that value?
First Author: Evan Y. Yu